Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md. , Dec. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference.

Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

GAITHERSBURG, Md. , Nov. 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Disney

Teladoc

These stocks suffered in 2022. And they have reason to rebound.

3 Potentially Explosive Stocks to Buy Before 2023

The shares are heading for almost a 90% loss this year.

Novavax Stock: Buy, Sell, or Hold in 2023?

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

A disagreement over a contract sent the stock tumbling.

Why Shares of Novavax Are Down Tuesday

Despite a strong rally seen in today's market, not all stocks are participating in the fun. One company that's currently sitting out this rally is vaccine maker Novavax (NASDAQ: NVAX ).

Novavax (NVAX) Stock Falls 10% After Ending Agreement With Gavi

Global vaccine alliance Gavi said on Tuesday it was not in breach of a deal to buy Novavax's COVID-19 vaccine and that it reserved all rights, including the recovery of advance payments to the company.

Gavi says it is not in breach of Novavax vaccine deal

Upstart Holdings

These beaten-down innovators have industry-changing potential.

Nasdaq Bear Market: 3 Remarkable Growth Stocks Down Over 90% That Can Double Your Money by 2025

Novavax Inc said on Monday it had delivered a written notice to Gavi, the Vaccine Alliance, terminating with immediate effect an agreement for the sale of the company's COVID-19 vaccine to low- and middle-income countries.

Novavax ends COVID vaccine sale agreement with Gavi

Novavax (NASDAQ: NVAX ) stock is on the move Friday after Canada approved the vaccine company's booster shot for Covid-19. That approval covers Nuvaxovid as a booster to prevent infection with Covid-19 in adults 18 and older.

What Is Going on With Novavax (NVAX) Stock Today?

Novavax Inc. (NASDAQ:NVAX) just received expanded authorization in Canada for its Coivd-19 booster.

Novavax Stock Brushes Off Vaccine Approval News

Shares of Novavax Inc. NVAX, -3.17% were up 2.4% in premarket trading on Friday after the company said its COVID-19 booster was authorized for adults in Canada who were previously immunized with Novavax's protein-based vaccine. The company's stock is down 85.4% this year, while the S&P 500 SPX, -0.31% has declined 17.2%.

Novavax's COVID-19 booster authorized in Canada

GAITHERSBURG, Md. , Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older.

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Netflix

Both companies performed well during the worst of the pandemic, but things have changed since then.

2 Cheap Stocks to Buy Right Now

Baidu

Fiverr

These amazing deals are ripe for the picking and poised to deliver triple-digit returns in five years.

Nasdaq Bear Market: 3 Phenomenal Bargains That Can Double Your Money by 2027

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

Novavax Inc. (NASDAQ:NVAX) stock is up 4.2% to trade at $20.48 this morning.

Vaccine Stock Higher After Revenue Beat

GAITHERSBURG, Md. , Nov. 9, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has expanded the conditional marketing authorization (CMA)i for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ as a homologous and heterologous booster dose after the primary series of Nuvaxovid (six months) or of an mRNA or adenoviral vector vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older.

Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

Novavax, Inc. (NASDAQ:NVAX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Silvia Taylor - Executive Vice President & Chief Communications Officer Stan Erck - President & Chief Executive Officer Filip Dubovsky - Chief Medical Officer John Trizzino - Chief Commercial Officer & Chief Business Officer Jim Kelly - Chief Financial Officer & Treasurer Conference Call Participants Roger Song - Jefferies Georgi Yordanov - Cowen and Company Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Vernon Bernardino - HC Wainwright Operator Good afternoon, and welcome to the Novavax Third Quarter 2022 Financial Results and Operational Highlights.

Novavax, Inc. (NVAX) Q3 2022 Earnings Call Transcript

The Covid-19 vaccine maker reported a net loss of more than $169 million for the third quarter, compared to a loss of $322 million in the same period last year.

Novavax posts third quarter loss but beats revenue expectations

Novavax Inc. on Tuesday tweaked its full-year sales outlook to the low end of its expected range and reported a surprise quarterly loss, but sales for the the COVID-19 vaccine maker were far better than expected.

News for Novavax Stock (NVAX)